StockNews.com Downgrades BioLineRx (NASDAQ:BLRX) to Sell

BioLineRx (NASDAQ:BLRX) was downgraded by StockNews.com from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Tuesday.

Separately, HC Wainwright lowered their target price on shares of BioLineRx from $840.00 to $360.00 and set a “buy” rating for the company in a report on Monday, November 25th.

BioLineRx Price Performance

BLRX opened at $3.39 on Tuesday. BioLineRx has a 12-month low of $2.88 and a 12-month high of $56.00. The company has a market cap of $11.29 million, a price-to-earnings ratio of -0.39 and a beta of 1.39. The company has a current ratio of 1.52, a quick ratio of 1.37 and a debt-to-equity ratio of 2.11. The stock has a fifty day simple moving average of $3.78 and a two-hundred day simple moving average of $12.09.

Institutional Investors Weigh In On BioLineRx

An institutional investor recently raised its position in BioLineRx stock. Atria Investments Inc increased its stake in shares of BioLineRx Ltd. (NASDAQ:BLRX) by 27.9% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 133,974 shares of the biotechnology company’s stock after purchasing an additional 29,193 shares during the period. Atria Investments Inc owned approximately 0.17% of BioLineRx worth $72,000 as of its most recent filing with the Securities & Exchange Commission. 1.56% of the stock is currently owned by institutional investors and hedge funds.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.